Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index; 36 of the 63 sources its claims cite were checked for support.

Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)

Open access
Peiffert, Mathilde, Cugnet-Anceau, Christine, Dalle, Stephane, Chikh, Karim, Assaad, Souad, Disse, Emmanuel, Raverot, Gérald, Borson-Chazot, Françoise, Abeillon-du Payrat, Juliette · 2021 · Cancers

Abstract

Thyrotoxicosis is an adverse event associated with immune checkpoint inhibitors (ICPis) that occurs in 0.6 to 3.2% of treated patients, depending on ICPi class. Presentation usually consists of a biphasic thyroiditis with transient thyrotoxicosis and secondary hypothyroidism. ICPi-induced Graves’ disease (GD), due to the stimulating activity of TSH-receptor autoantibodies (TRAb), is extremely rare. The aim of this retrospective study was to describe the characteristics and evolution of GD during ICPi therapy. Five among 243 patients followed for ICPi-induced thyrotoxicosis showed TRAb positivity (2% of the cohort). GD occurred quickly after initiation of ICPis; its course was typical for two patients, with prolonged requirement for antithyroid drug treatment (ATD). The three other patients experienced biphasic thyroiditis with secondary hypothyroidism requiring long-term substitution. Three other patients had a diagnosis of GD before starting ICPis; they evolved toward hypothyroidism with early cessation of ATD and long-term substitution treatment during ICPi treatment. None developed significant Graves’ orbitopathy. ICPi treatment was not interrupted for thyroid dysfunction. In conclusion, GD is a rare, immune-related adverse event of ICPis with an unusual course and frequent evolution to biphasic thyroiditis. In the case of ICPi-induced thyrotoxicosis in the presence of TRAb, observing the spontaneous evolution and performing a scintigraphy are useful before starting ATD treatment. Pre-existing GD is not exacerbated by ICPis and tends to evolve towards hypothyroidism. ICPi treatment can be maintained with adequate biochemical surveillance.

Overview

CoChat Summary

TL;DR

In a retrospective Lyon cohort of 243 patients with ICPi-induced thyrotoxicosis, 5 (2%) had TRAb-positive induced Graves’ disease and 3 had pre-existing Graves’ disease. Induced GD often followed an atypical course, with 3/5 evolving to hypothyroidism, while pre-existing GD uniformly evolved to hypothyroidism; no severe hyperthyroidism or significant orbitopathy occurred and ICPi was maintained.

Key findings

  • Among 243 patients referred for thyrotoxicosis during ICPi treatment, 5 (2%) had TRAb-positive ICPi-induced GD; 3 additional patients had pre-existing GD before starting ICPis.
  • In induced GD, 2/5 had a typical Graves’ course requiring prolonged antithyroid drug treatment (about one year for patient 1; patient 2 was still on ATD after 6 months because tapering caused recurrence), while 3/5 had transient thyrotoxicosis and evolved to hypothyroidism requiring long-term substitution.
  • All 3 patients with pre-existing GD developed secondary hypothyroidism with early ATD cessation and long-term levothyroxine; none developed irAE. None of the 8 patients developed significant Graves’ orbitopathy or severe hyperthyroidism, and ICPi treatment was not interrupted for thyroid dysfunction.
  • The literature review found only nine reported cases of ICPi-induced Graves’ hyperthyroidism and seven of induced Graves’ orbitopathy, with one patient having both; all eight induced GD cases without orbitopathy had TRAb positivity and/or high iodine uptake, and only one evolved to spontaneous hypothyroidism.

Methods

  • Retrospective descriptive cohort study with longitudinal follow-up at the University Hospital of Lyon, France, from December 2015 to December 2020, via the ImmuCare and Tox’imm networks; included adults with thyrotoxicosis diagnosed at pre-therapeutic screening or during ICPi treatment for any cancer and positive TRAb.
  • Thyrotoxicosis was defined as low TSH (normal 0.4–4 mUI/L) with high FT4 (normal 12–22 pmol/L) and/or high FT3 (normal 3.1–6.8 pmol/L); TRAb positivity was >1.6 UI/L, TPOAb positivity >34 UI/mL; scintigraphy/ultrasound were used when required; secondary hypothyroidism was high TSH with low FT4/FT3 without thyroid treatment.
  • The paper also reviews published cases of ICPi-induced Graves’ hyperthyroidism and orbitopathy (Table 3).

Limitations

  • Stated: the series is small (5 induced GD, 3 pre-existing GD), retrospective, and from a single tertiary referral center; the authors state the 2% TRAb-positive prevalence is probably an overestimate because patients with mild thyrotoxicosis may not have been referred.
  • Stated: TRAb bioassays could not be performed to distinguish stimulating from blocking antibodies, and no information was available on time to TRAb negativity in the induced GD patients.
  • Evident from the text: there was no control group; ICPi regimens, cancer types, follow-up frequency, and scintigraphy timing were heterogeneous, and the literature comparison relies on case reports.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers13081944

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flow chart. ICPis: immune checkpoint inhibitors; TRAb: TSH-receptor autoantibodies.
Figure 1 Flow chart. ICPis: immune checkpoint inhibitors; TRAb: TSH-receptor autoantibodies.CC BY · PubMed Central
Figure 2 Evolution of thyroid dysfunction. (A) Patient no. 1; (B) Patient no. 3; (C) Patient no. 6. TSH: thyroid stimulating hormone; FT4: free thyroxine; ICPi: immune checkpoint inhibitor; ATD: antithyroid drug therapy; irAE: immune-related adverse event; GC: glucocorticoids; TRAb: TSH-receptor autoantibodies; LVT: levothyroxine.
Figure 2 Evolution of thyroid dysfunction. (A) Patient no. 1; (B) Patient no. 3; (C) Patient no. 6. TSH: thyroid stimulating hormone; FT4: free thyroxine; ICPi: immune checkpoint inhibitor; ATD: antithyroid drug therapy; irAE: immune-related adverse event; GC: glucocorticoids; TRAb: TSH-receptor autoantibodies; LVT: levothyroxine.CC BY · PubMed Central

Verification

Claims the paper makes

19 Valid · 3 Not valid · 9 Not checked · 37 Own results and interpretations

29 more claims · 6 with their cited sources checked

Create a free account to see all 68 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 67 references

Cited by

See all 33

Metadata

Authors
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J.
Affiliations
  • Lyon 1 Université (FR)
  • Service d’Endocrinologie-Diabète-Nutrition, Hôpital Lyon Sud, Hospices Civils de Lyon, 69310 Pierre-Bénite, France
  • Faculté de Médecine, Université Lyon 1, 69008 Lyon, France
  • Centre Léon Bérard (FR)
  • Fédération d’Endocrinologie, Hôpital Louis Pradel, Groupement Hospitalier Est, Hospices Civils de Lyon, 69500 Bron, France
Corresponding author
Peiffert, Mathilde
Venue
Cancers
Publisher
MDPI AG
Published
2021-04-17
Volume
13
Issue
8
Pages
1944
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3156514035
Cited by
33
References
67
Citations by year
2026: 1 · 2025: 6 · 2024: 3 · 2023: 9 · 2022: 11 · 2021: 3
FWCI
4.85
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
Keywords
Graves' disease, immune checkpoint inhibitors, immune-related adverse events, thyrotoxicosis, TSH receptor antibodies, central hypothyroidism, antithyroid drugs, Graves' ophthalmopathy, thyroid scintigraphy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). https://app.cochat.ai/papers/10.3390/cancers13081944
The paper
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021). Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). Cancers. https://doi.org/10.3390/cancers13081944

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.